Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: August 30, 2010
Last updated: March 1, 2011
Last verified: September 2010
In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Condition Intervention
Drug: Ovitrelle

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • number of oocytes retrieved [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: April 2011
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ovitrelle supplemantation
The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
Drug: Ovitrelle
One dose of Ovitrelle 250 mcg
No Intervention: no Ovitrelle supplementation


Ages Eligible for Study:   40 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women >39 years on IVF treatment

Exclusion Criteria:

  • polycystic ovary syndrome
  • Any allergy to injection of human chorionic gonadotropin before
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01205009

Contact: Mushira Aboo Dia, , MD
Contact: Hadas Lemberg, PhD 00 972 2 6777572

Hadassah Medical Center Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    0097226776095   
Contact: Mushira Aboo Dia, MD    0097226776425   
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Mushira Aboo Dia, MD Hadassah Medical Center
  More Information

No publications provided

Responsible Party: Arik Tzukert, Hadassah Medical Center Identifier: NCT01205009     History of Changes
Other Study ID Numbers: hCGpoorresp-HMO-CTIL
Study First Received: August 30, 2010
Last Updated: March 1, 2011
Health Authority: Israel: Ministry of Health - Director General

Keywords provided by Hadassah Medical Organization:
in-vitro fertilization
poor responders
human chorionic gonadotropin
Fertility Agents, Female

Additional relevant MeSH terms:
Chorionic Gonadotropin
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 27, 2015